OncoExTra® Tissue Genomic Profiling test
The OncoExTra test identifies biomarkers that can help guide therapy selection for patients with advanced, metastatic, refractory, relapsed, or recurrent solid tumors.
Benefits of the OncoExTra test
Insights that turn unknowns into answers
There are actionable variants that could be missed by fixed-panel tests. The OncoExTra test utilizes whole-exome and whole-transcriptome sequencing across nearly 20,000 genes to deliver more answers — all in one test.1 *
All-encompassing genomic profiling
By interrogating both DNA and RNA, the OncoExTra test provides all-encompassing genomic profiling that thoroughly detects clinically actionable mutations and fusions.1 And when you add on optional immunohistochemical (IHC) stains or tumor-specific panels, you’ll uncover even more biomarker detail for more personalized care.†
Clinically actionable results
The OncoExTra report highlights the most clinically relevant information, to support prompt, point-of-care discussions between providers and their patients, leading to shared treatment decisions.
Patient-matched tumor-normal sequencing
The OncoExTra test utilizes patient-matched tumor-normal sequencing to further refine therapy selection. Comparing the sequence of genes in both somatic and germline DNA, this matched sequencing helps identify true somatic alterations, improves tumor mutational burden (TMB) calculation, and may better predict clinical benefit to immunotherapy with fewer false positives.2-4
In a study of over 10,000 advanced solid tumors, 92% of reports came back with at least one therapeutically actionable variant5
Have questions?
Call us at 1 866-662-6897 .